H(2)-receptor antagonists, such as cimetidine, ranitidine and famotidine, are some of the most commonly prescribed medications for gastric acid-related disorders. These compounds are generally well-tolerated and anaphylactic reactions to them are rare. Here, we report two cases of H(2)-receptor antagonist-induced anaphylactic reactions: the first presented with sudden dyspnea, sneezing, urticaria, and swelling of the eyelids after ranitidine intake. The second presented with sudden severe urticaria, facial swelling, chest discomfort, dizziness, and hypotension. Possible cross-reactivity with other H(2)-receptor antagonists was assessed by oral challenge and skin tests. To date, only a few reports addressing cross-reactivity among H(2)-receptor antagonists have been published. We review the literature and summarize the data available on drug cross-reactivity in H(2)-receptor antagonist hypersensitivity.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3062792 | PMC |
| http://dx.doi.org/10.4168/aair.2011.3.2.128 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Difluorinated thromboxane A reveals crosstalk between platelet activatory and inhibitory pathways by targeting both the TP and IP receptors.
Br J Pharmacol
October 2024
School of Physiology, Pharmacology and Neuroscience, Faculty of Life Sciences, University of Bristol, Bristol, UK.
Background And Purpose: Thromboxane A (TXA) is a prostanoid produced during platelet activaton, important in enhancing platelet reactivity by activation of TP receptors. However, due to the short half-life, studying TXA signalling is challenging. To enhance our understanding of TP receptor-mediated platelet biology, we therefore synthesised mono and difluorinated TXA analogues and explored their pharmacology on heterologous and endogenously expressed TP receptor function.
View Article and Find Full Text PDFPractical Three-Component Regioselective Synthesis of Drug-Like 3-Aryl(or heteroaryl)-5,6-dihydrobenzo[]cinnolines as Potential Non-Covalent Multi-Targeting Inhibitors To Combat Neurodegenerative Diseases.
ACS Chem Neurosci
May 2024
Department of Organic Chemistry, Faculty of Chemistry, Urmia University, Urmia 5756151818, Iran.
Neurodegenerative diseases (NDs) are one of the prominent health challenges facing contemporary society, and many efforts have been made to overcome and (or) control it. In this research paper, we described a practical one-pot two-step three-component reaction between 3,4-dihydronaphthalen-1(2)-one (), aryl(or heteroaryl)glyoxal monohydrates (-), and hydrazine monohydrate (NHNH•HO) for the regioselective preparation of some 3-aryl(or heteroaryl)-5,6-dihydrobenzo[]cinnoline derivatives (-). After synthesis and characterization of the mentioned cinnolines (-), the multi-targeting inhibitory properties of these heterocyclic scaffolds have been investigated upon various -type enzymes, including MAO-A, MAO-B, AChE, BChE, BACE-1, BACE-2, NQO-1, NQO-2, nNOS, iNOS, PARP-1, PARP-2, LRRK-2, GSK-3β, p38α MAPK, JNK-3, OGA, NMDA receptor, nSMase-2, IDO-1, COMT, LIMK-1, LIMK-2, RIPK-1, UCH-L1, PARK-7, and DHODH, which have confirmed their functions and roles in the neurodegenerative diseases (NDs), based on molecular docking studies, and the obtained results were compared with a wide range of approved drugs and well-known (with IC, EC, etc.
View Article and Find Full Text PDFStructure of the murine CD94-NKG2A receptor in complex with Qa-1 presenting an MHC-I leader peptide.
FEBS J
April 2024
Infection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Australia.
The heterodimeric natural killer cells antigen CD94 (CD94)-NKG2-A/NKG2-B type II integral membrane protein (NKG2A) receptor family expressed on human and mouse natural killer (NK) cells monitors global major histocompatibility complex (MHC) class I cell surface expression levels through binding to MHC class Ia-derived leader sequence peptides presented by HLA class I histocompatibility antigen, alpha chain E (HLA-E; in humans) or H-2 class I histocompatibility antigen, D-37 (Qa-1; in mice). Although the molecular basis underpinning human CD94-NKG2A recognition of HLA-E is known, the equivalent interaction in the murine setting is not. By determining the high-resolution crystal structure of murine CD94-NKG2A in complex with Qa-1 presenting the Qa-1 determinant modifier peptide (QDM), we resolved the mode of binding.
View Article and Find Full Text PDFTargeted vaccine development against Bilophila wadsworthia to curb colon diseases: A multiepitope approach based on reverse vaccinology and computational analysis.
Int J Biol Macromol
October 2023
Institute of Biotechnology and Genetic Engineering, The University of Agriculture, Peshawar 25130, Pakistan. Electronic address:
The presence of excessive hydrogen sulfide (HS)-producing bacteria, particularly Bilophila wadsworthia in appendices, is linked to a weaker colonic mucus barrier, inflammatory bowel disease, and colorectal cancer. Thus, targeting this bacterium could reduce sulfide levels and address associated health concerns. Here, we utilized reverse vaccinology and immunoinformatics to design a chimeric vaccine against B.
View Article and Find Full Text PDFThe next generation virus-like particle platform for the treatment of peanut allergy.
Allergy
July 2023
Department of Immunology, University Clinic of Rheumatology and Immunology, Inselspital, Bern, Switzerland.
Background: Allergy to peanut is one of the leading causes of anaphylactic reactions among food allergic patients. Immunization against peanut allergy with a safe and protective vaccine holds a promise to induce durable protection against anaphylaxis caused by exposure to peanut. A novel vaccine candidate (VLP Peanut), based on virus-like particles (VLPs), is described here for the treatment of peanut allergy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!